No profile data available.
Edgewise Therapeutics, Inc. (EWTX) is a healthcare company in the brain and nerve treatment drugs industry, based in Boulder, United States, with about 127 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$167.80 million. Its market capitalization was $4.24 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Edgewise Therapeutics reported $0 in revenue for fiscal year 2025.
$4.24 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Praxis Precision Medicines, Inc. (PRAX), Dianthus Therapeutics, Inc. (DNTH), Acadia Pharmaceuticals Inc. (ACAD), Xenon Pharmaceuticals Inc. (XENE).